RCT of rapamycin and everolimus in older adults tested pharmacokinetics and pharmacodynamics of mTOR inhibition.
RESTOR was an exploratory pharmacokinetic/pharmacodynamic study that tested two mTOR inhibitors (rapamycin and everolimus) in healthy older adults. The study aimed to identify doses that could safely inhibit mTOR to levels seen in young people, with attention to potential sex differences in optimal dosing. No efficacy outcomes or clinical benefits were reported.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jun 1, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Healthy older adults, including both male and female subjects
- Primary outcome
- Safe inhibition of mTOR to levels seen in young healthy persons; pharmacokinetics and pharmacodynamics of mTOR inhibitors in older subjects
- Effect size
- —
- Significance
- Not reported
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Jun 1, 2026
Sources
Primary source
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.